Aptadel Therapeutcs technology is based in RNA-Aptamers. We use our Aptamers as a platform tool to deliver different therapeutic agents with high specificity and improved safety to treat a wide variety of cancers.
Changing The Way We Treat Cancer
Aptamer-related technologies represent a revolutionary advancement in the capacity to rapidly develop new classes of targeting ligands. Structurally distinct RNA and DNA oligonucleotides, aptamers mimic small, protein-binding molecules and exhibit high binding affinity and selectivity.
Although their molecular weight is relatively small-approximately one-tenth that of monoclonal antibodies-their complex tertiary folded structures create enough recognition surface area for tight interaction with target molecules.
Additionally, unlike antibodies, aptamers can be readily chemically synthesized and modified. Due to their flexibility of chemical modification, aptamers are conjugated to other chemical entities including chemotherapeutic agents, siRNA, nanoparticles, and solid phase surfaces for therapeutic and diagnostic applications. By cell-internalization SELEX we have generated an Aptamer specific for the tyrosine-kinase receptor EphA2, implicated in many processes crucial to malignant progression, such as migration, invasion, metastasis, proliferation, survival, and angiogenesis. We propose a radically innovative treatment for EphA2 expressing tumors based on multifunctional RNA-based molecules targeting the expression of a key target, a fusion protein in the case of translocation-associated sarcomas and the EphA2 tyrosine kinase receptor.
Combination of protein and cell internalization SELEX identifies a potential RNA therapeutic and delivery platform to treat EphA2-expressing tumors
Laura Santana-Viera, Justin P Dassie, Marta Rosàs-Lapeña, Silvia Garcia-Monclús , Mariona Chicón-Bosch, Marina Pérez-Capó, Lidia Del Pozo, Sara Sanchez-Serra, Olga Almacellas-Rabaiget, Susana Maqueda-Marcos, Roser López-Alemany, William H Thiel, Paloma H Giangrande, Oscar M Tirado
Mol Ther Nucleic Acids. 2023 May 8; 32:758-772
EphA2 receptor is a key player in the metastatic onset of Ewing Sarcoma
Silvia Garcia-Monclús, Roser López-Alemany, Olga Almacellas-Rabaiget, David Herrero-Martín, Juan Huertas-Martinez, Laura Lagares-Tena, Piedad Alba-Pavón, Lourdes Hontecillas-Prieto, Jaume Mora, Enrique de Álava, Santi Rello-Varona, Paloma H. Giangrande, and Oscar M Tirado
Int J Cancer. 2018 Sep 1; 143(5): 1188–1201.
EphA2-induced angiogenesis in Ewing Sarcoma cells works through bFGF production and is dependent on caveolin-1
Miguel Sáinz-Jaspeado, Juan Huertas-Martinez, Laura Lagares-Tena, Juan Martin Liberal, Silvia Mateo-Lozano, Enrique de Alava, Carmen de Torres, Jaume Mora, Xavier Garcia del Muro, and Oscar M. Tirado
PLoS One. 2013; 8(8): e71449.